BACKGROUND AND OBJECTIVES: During the past decade, nephrogenic systemic fibrosis (NSF) has been reported in patients who have severe renal impairment and have been exposed to a gadolinium (Gd)-based contrast agent during magnetic resonance imaging (MRI). As a result of positive reporting bias, many suitable patients with chronic kidney disease (CKD) are being denied a highly important form of investigation that can be safely undertaken. We analyzed the safety of Gd-MRI in patients with CKD and varying levels of estimated GFR (eGFR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective analysis of 2053 unselected patients who had CKD and had received Gd-MRI between 1999 and 2009, so as to determine the risk for NSF related to level of CKD, nature of Gd preparation, and Gd dosage. RESULTS: Overall, 2053 patients (63.5% men; mean age 60.6 +/- 15.7 years) had 2278 Gd-MRI scans; their mean eGFR was 40.7 +/- 23.7 ml/min. A total of 918 (44.7%) patients had stage 3, 491 (23.9%) had stage 4, and 117 (5.7%) had predialysis stage 5 CKD. No cases of NSF were identified during an average follow-up period of 28.6 +/- 18.2 months. CONCLUSIONS: In this study, no patients developed NSF during extended follow-up, even after multiple Gd doses in some. Gd-MRI can be safely undertaken in the majority of patients with CKD, but caution is merited for dialysis patients and those with acute kidney injury, with relative caution for predialysis patients with stage 5 CKD.
BACKGROUND AND OBJECTIVES: During the past decade, nephrogenic systemic fibrosis (NSF) has been reported in patients who have severe renal impairment and have been exposed to a gadolinium (Gd)-based contrast agent during magnetic resonance imaging (MRI). As a result of positive reporting bias, many suitable patients with chronic kidney disease (CKD) are being denied a highly important form of investigation that can be safely undertaken. We analyzed the safety of Gd-MRI in patients with CKD and varying levels of estimated GFR (eGFR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective analysis of 2053 unselected patients who had CKD and had received Gd-MRI between 1999 and 2009, so as to determine the risk for NSF related to level of CKD, nature of Gd preparation, and Gd dosage. RESULTS: Overall, 2053 patients (63.5% men; mean age 60.6 +/- 15.7 years) had 2278 Gd-MRI scans; their mean eGFR was 40.7 +/- 23.7 ml/min. A total of 918 (44.7%) patients had stage 3, 491 (23.9%) had stage 4, and 117 (5.7%) had predialysis stage 5 CKD. No cases of NSF were identified during an average follow-up period of 28.6 +/- 18.2 months. CONCLUSIONS: In this study, no patients developed NSF during extended follow-up, even after multiple Gd doses in some. Gd-MRI can be safely undertaken in the majority of patients with CKD, but caution is merited for dialysis patients and those with acute kidney injury, with relative caution for predialysis patients with stage 5 CKD.
Authors: Emanuel Kanal; A James Barkovich; Charlotte Bell; James P Borgstede; William G Bradley; Jerry W Froelich; Tobias Gilk; J Rod Gimbel; John Gosbee; Ellisa Kuhni-Kaminski; James W Lester; John Nyenhuis; Yoav Parag; Daniel J Schaefer; Elizabeth A Sebek-Scoumis; Jeffrey Weinreb; Loren A Zaremba; Pamela Wilcox; Leonard Lucey; Nancy Sass Journal: AJR Am J Roentgenol Date: 2007-06 Impact factor: 3.959
Authors: Dale R Broome; Mark S Girguis; Pedro W Baron; Alfred C Cottrell; Ingrid Kjellin; Gerald A Kirk Journal: AJR Am J Roentgenol Date: 2007-02 Impact factor: 3.959
Authors: M Maloo; P Abt; R Kashyap; D Younan; M Zand; M Orloff; A Jain; A Pentland; G Scott; A Bozorgzadeh Journal: Am J Transplant Date: 2006-06-19 Impact factor: 8.086
Authors: Gertraud Heinz-Peer; Anita Neruda; Bruno Watschinger; Andreas Vychytil; Alexandra Geusau; Markus Haumer; Michael Weber Journal: Eur J Radiol Date: 2009-07-19 Impact factor: 3.528
Authors: Fabian A Mendoza; Carol M Artlett; Nora Sandorfi; Kevin Latinis; Sonsoles Piera-Velazquez; Sergio A Jimenez Journal: Semin Arthritis Rheum Date: 2006-02 Impact factor: 5.532
Authors: Qinxue Sun; Maike Baues; Barbara M Klinkhammer; Josef Ehling; Sonja Djudjaj; Natascha I Drude; Christoph Daniel; Kerstin Amann; Rafael Kramann; Hyojin Kim; Julio Saez-Rodriguez; Ralf Weiskirchen; David C Onthank; Rene M Botnar; Fabian Kiessling; Jürgen Floege; Twan Lammers; Peter Boor Journal: Sci Transl Med Date: 2019-04-03 Impact factor: 17.956
Authors: Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein Journal: Ann Intern Med Date: 2020-06-23 Impact factor: 25.391
Authors: Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873